Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
Philips’s CavaClear is intended to safely ablate tissue to remove embedded IVC filters
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
Subscribe To Our Newsletter & Stay Updated
